Tenders Are Invited For Open House Contracts For Multiple Active Ingredients/Active Ingredient Combinations in Germany

Work Detail

Open House Contracts For Multiple Active Ingredients/Active Ingredient Combinations. The Subject Of This Publication Is The Conclusion Of Contracts In Accordance With Section 130A (8) Sgb V For The Following Active Substances/Combinations Of Active Substances As Part Of A So-Called Open-House Procedure: Clobetasol (D07ad01) Dasatinib (L01ea02) Dexamethasone & Gentamicin (S01ca21) Melatonin (N05ch01) Sodium Oxybate (N01ax11, N07xx04) Permethrin (P03ac04) Tafluprost (S01ee05) Telmisartan & Amlodipine (C09db04) Therapy Allergen Trees (V01aa05) Therapy Allergen Grasses (V01aa02) Therapy Allergen Mite (V01aa03) Therapy Allergen Scit (V01aa02, V01aa03, V01aa05) Trientine (A16ax12) With The Specification Of Uniform Contract Conditions And A Uniform Access Procedure, All Suitable And Interested Pharmaceutical Companies Or Groups Of Pharmaceutical Companies Are Offered The Opportunity To Conclude A Discount Agreement In Accordance With § 130A Paragraph 8 Sgb V For The Active Ingredients/Active Ingredient Combinations Mentioned. The Earliest Contract Start Date Is April 1St, 2023. Based On This, The Contract Term Is A Maximum Of 24 Months.

Contact Information